Together we’re better
Patient Focused Tele-Health, LLC is actively seeking the correct industry partners to License (exclusively or non-exclusively) our proprietary Advanced Penetration Technology™ platform. PFTH has no doubt as to the dramatically improved efficacy, created by utilizing the APT™ platform, within non-prescription (OTC) categories of topical therapeutics. We also believe the APT™ will enhance any prescription topical product that has the correct chemical structure.
The ability to take existing, approved product platforms and create a category leading product can transform the market specific opportunities on a global scale.
Example: A highly effective, Non-Prescription therapy for Nail Fungal infections. Currently a global market opportunity of $3.1 billion, with a CAGR of 8.3%1. Regardless of other product claims, we have seen our Terbinafine 1% ointment effectively clear nail fungal infections in weeks, not months.
The proof is in the results
Currently PFTH has studies in progress for further validation of the efficacy of our Tetracycline 3% ointment on the most pathogenic and resistant bacteria in medicine. This information will be available by 5/2019.
PFTH also has a nail penetration study ongoing with results available in 4/2019. This will substantiate the penetration ability of the APT™ platform in delivering medications down deep into keratin and disrupted keratin.
1 Global Market Study on Dermatophytic Oncychomycosis Therapeutics (DOT): January 18, 2016. Persistence Market Research: 305 Broadway, 7th Floor New York City, NY. 10007
COVID-19 (Coronavirus) is a pandemic with no immediate vaccines, treatments or preventative products
The United States and international health providers, pharmaceutical companies and governments are actively
working to fund these vital initiatives. Social distancing, with its associated shutdown of commerce
and normal routine appears, to be the best solution so far in preventing the spread of the COVID virus.
Based on scientific research, Advanced Penetration Technology, LLC strongly believes the proprietary APT™
based non-prescription (OTC) topical formulation, used off-label, will play an important role in
mitigating, decreasing and preventing the spread and severity of COVID-19 illness.
Recently concluded Anti-Viral Studies demonstrated the significant efficacy of the APT™ T3X formulation in
neutralizing the Influenza A virus (H1N1) and Coronavirus (NL63). The laboratory conclusion
was “Under the conditions tested, treatment of influenza A/WSN/33 virus
and Coronavirus NL63, with APT™ T3X formulation abolishes infectivity”. Further viral
testing is ongoing.
Decreasing the Viral Load of Exposure is the key to slowing and mitigating
the spread of COVID-19 virus. The daily use of APT™ T3X formulation as a nasal swab application will help
in the mitigation of the COVID-19 Pandemic.
- Application recommendations for Healthcare Workers, Military personnel, First Responders, (at) High
risk individuals and the General Public: Swabbing the formulation within each nasal cavity every
12 hours could reduce the exposure levels of the COVID-19 virus into the body, hence reducing
infectivity of the individual and decreasing transmission to others.
- Application recommendations for Non-symptomatic COVID-19 patients: Swabbing the product within
the nasal cavity every 12 hours to mitigate infectivity, transmission and progression of the
- APT™ T3X formulation use along with recommended CDC guidelines for COVID-19 prevention, together,
create another barrier to infection and transmission to fight this Pandemic.